FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per	
resnonse	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Type Responses)										
Name and Address of Reporting Person BAKER BROS. ADVISORS LP		ssuer Name and Ticker or	Trading Symbol					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
(Last) (First) (Middle)		MA Corp [XOMA] te of Earliest Transaction	Month/Dav/Year)					X_ Director		
667 MADISON AVENUE, 21ST FLOOR	12/2	6/2014								
(Street)	4. If A	Amendment, Date Origina	Filed(Month/Day/Yea	r)				5. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person		
NEW YORK, NY US 10065								X_Form filed by More than One Reporting Person		
(City) (State) (Zip)				Table l	- Non-Der	ivative Sec	curities Acquir	red, Disposed of, or Beneficially Owned		
1. Title of Security	2. Transaction Da		3. Transaction Co	de		s Acquired	l (A) or	5. Amount of Securities Beneficially Owned Following Reported	6.	7. Nature
(Instr. 3)	(Month/Day/Year	any	(Instr. 8)		Disposed of (Instr. 3, 4			Transaction(s) (Instr. 3 and 4)	Ownership Form:	Beneficial
		(Month/Day/Year)							Direct (D) or Indirect	Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price		(I) (Instr. 4)	
						(-)			(See
Common Stock	12/26/2014		S		15,420	D	\$ 3.7106	2,186,603	I	footnote
										(2) (7)
Common Stock	12/26/2014		S		112,855	D	\$ 3.7106	15,022,732	T	See footnote
Common Stock	12/20/2014		3		112,033	Ь	<u>(1)</u>	15,022,752		(3) (7)
							6 2 7106			See
Common Stock	12/26/2014		S		2,825	D	\$ 3.7106 (1)	405,778	I	footnote (4) (7)
Common Stock	12/29/2014		S		26,137	D	\$ 3.6762	2,160,466	I	See footnote
					.,		<u>(5)</u>	,,		(2) (7)
							\$ 3.6762			See
Common Stock	12/29/2014		S		190,117	D	(5)	14,832,615	I	footnote (3) (7)
										See
Common Stock	12/29/2014		S		4,746	D	\$ 3.6762 (5)	401,032	I	footnote
							157			(4) (7)
Common Stock	12/30/2014		S		46.262	D	\$ 3.6495	2 114 104	т	See footnote
Common Stock	12/30/2014		3		46,362	D	<u>(6)</u>	2,114,104	1	(2) (7)
							0.0.640#			See
Common Stock	12/30/2014		S		337,123	D	\$ 3.6495 (6)	14,495,492	I	footnote
										(3) (7)
Common Stock	12/30/2014		S		8,415	D	\$ 3.6495	392,617	T	See footnote
Common Stock	12/30/2011				0,115		<u>(6)</u>	5,2,017	•	<u>(4) (7)</u>
Reminder: Report on a separate line for each class of securities beneficially owned	directly or indirect	tly.	Pe	rsons v	vho respo	nd to the	collection of	information contained in this form are not required to	SEC	1474 (9-02)
			res	pond (ınless the	form disp	plays a curre	ntly valid OMB control number.		
		Table II - Derivative Sec					wned			
Title of Derivative Security 2. Conversion or 3. Transaction Date 3A. D	eemed 4. 7		, warrants, option umber of Derivativ			rities) Exercisable	and 7. Title	and Amount of Underlying 8. Price of 9. Number of	10.	11. Nature
(Instr. 3) Exercise Price of Derivative (Month/Day/Year) Execu		str. 8) Secu	rities Acquired (A) osed of (D)		Expiration		Securit		Ownership Form of	
	h/Day/Year)		r. 3, 4, and 5)		(WORLD)	Jugi I cal)	(mstr.	(Instr. 5) Beneficially	Derivative	Ownership
					Date	E.		Owned Following	Security: Direct (D)	(Instr. 4)
					Exercisa Exercisa		ration Title	Transaction(s)	or Indirect (I)	
		Code V	(A)	(D)				(Instr. 4)	(Instr. 4)	

Reporting Owners

		Relationships				
Reporting Owner Name / Address		10% Owner	Officer	Other		
BAKER BROS. ADVISORS LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X				
667, L.P. 667 MADISON AVENUE 21ST FLOOR NEW YORK, NY US 10065	X	X				
Baker Brothers Life Sciences LP 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X				
14159, L.P. 667 MADISION AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X				
Baker Bros. Advisors (GP) LLC 667 MADISION AVENUE 21ST FLOOR NEW YORK, NY US 10065	X	X				
BAKER FELIX 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X				
BAKER JULIAN 667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY US 10065	X	X				

Signatures

]	By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing Title: President /s/ Scott L. Lessing	12/30/2014	

Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing	12/30/2014
**Signature of Reporting Person	Date
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P Name:Scott L. Lessing, Title: President /s/	12/30/2014
**Signature of Reporting Person	Date
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 14159, L.P., pursuant to authority granted by 14159 Capital, L.P., GP to 14159, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing	12/30/2014
**Signature of Reporting Person	Date
Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing Title: President /s/ Scott L. Lessing	12/30/2014
**Signature of Reporting Person	Date
/s/ Felix J. Baker	12/30/2014
**Signature of Reporting Person	Date
/s/ Julian C. Baker	12/30/2014
"Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The price reported in Column 4 is a weighted average price. These shares were sold by each of Baker Brothers Life Sciences, L.P. ("Life Sciences"), 14159, L.P. ("14159"), and 667, L.P. ("667", and together with Life Sciences and 14159, the "Funds") in multiple transactions at prices rate the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
- (2) After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Biotech Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
- (3) After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker acts may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock report Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., to the Baker Brothers Life Sciences Capital, L.P. is right to receive an allocation of a portion of the profits from Life Sciences.
- (4) After giving effect to the transactions reported herein and as a result of their ownership interest in 14159 Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Tab partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital, L.P.'s right to receive an allocation of a portion of the profits from 14159.
- (5) The price reported in Column 4 is a weighted average price. These shares were sold by the Funds in multiple transactions at prices ranging from \$3.65 to \$3.79, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securiti price within the range set forth in this footnote.
- (6) The price reported in Column 4 is a weighted average price. These shares were sold by the Funds in multiple transactions at prices ranging from \$3.60 to \$3.70, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Security price within the range set forth in this footnote.
- Baker Bros. Advisors LP ("the Adviser") serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bro are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds have relinquished to the Adviser all discretion and authority with respect to the investment and dispositive power over the stock options and restricted to kin service on the Board of Directors of the Issuer (the "Board") and any shares received as a result of the exercise of stock options or the ves Neu does not have any right to any of the Issuer's securities issued as part of his service on the Board, and the Funds are entitled to receive all the pecuniary interest in the securities issued. Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

Remarks:

Dr. Kelvin Neu, an employee of Baker Bros. Advisors LP, is a director of Xoma Corporation (the "Issuer"). By virtue of his representation on the Board of Directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.